Brief: Surface Oncology Initiates Phase 2 Studies Evaluating SRF388
14/04/2022 12:32
April 14 (Reuters) - Surface Oncology Inc SURF.O :
* SURFACE ONCOLOGY ANNOUNCES INITIATION OF PHASE 2 STUDIES
EVALUATING SRF388 IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AND
NON-SMALL-CELL LUNG CANCER
Source text for Eikon: ID:nGNX177htN
Further company coverage: SURF.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Surface Oncology
See all newsBrief: Surface Oncology Says Anticipates Will Have Net Cash Of $20 Million To $25 Million At The Closing Of The Proposed Mergers
Surface Oncology Inc reports results for the quarter ended in June - Earnings Summary
Brief: Surface Oncology, Inc. Q2 Net Income USD -28.2 Mln
Surface Oncology Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: ADAR1 Partners Reports 5.24% Passive Stake In Surface Oncology Inc As Of July 10 - SEC Filing